Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

The Lung Cancer Research Foundation (LCRF) is pleased to announce its partnership with Israel Cancer Research Fund (ICRF) on a project led by Joel Yisraeli, PhD, and his lab in the Department of ...

The leading Metastatic Pancreatic Cancer Companies such as Xencor, MEI Pharma, Celldex Therapeutics, TG Therapeutics, ...

Inhibition of nonsense-mediated decay turns immunologically cold tumors hot by increasing the amount of mutant RNA leading to an increase in T-cell-targetable neoantigens on the cell surface.

Pancreatic cancer, one of the most aggressive and lethal types of cancer, continues to present significant challenges in both its detection and treatment. The lack of early detection tools, coupled ...

Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

Medical experts discuss approaches to patient education on managing potential adverse events associated with adagrasib and other KRAS-targeted therapies.

Angela will provide an update from our earlier stage programs, including our BCL6 degrader, ARV-393; and our KRAS G12D degrader. And finally ... we intend to initiate a Phase 3 trial with vepdeg plus ...

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

DelveInsight’s, “Metastatic Colorectal Cancer Pipeline Insight” report provides comprehensive insights about 80+ companies ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.